PL4142733T3 - Inhibitory deacetylazy histonowej do immunomodulacji w mikrośrodowisku guza - Google Patents
Inhibitory deacetylazy histonowej do immunomodulacji w mikrośrodowisku guzaInfo
- Publication number
- PL4142733T3 PL4142733T3 PL21796395.8T PL21796395T PL4142733T3 PL 4142733 T3 PL4142733 T3 PL 4142733T3 PL 21796395 T PL21796395 T PL 21796395T PL 4142733 T3 PL4142733 T3 PL 4142733T3
- Authority
- PL
- Poland
- Prior art keywords
- immunomodulation
- histone deacetylase
- tumor microenvironment
- deacetylase inhibitors
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063018427P | 2020-04-30 | 2020-04-30 | |
| PCT/CN2021/090718 WO2021219040A1 (en) | 2020-04-30 | 2021-04-28 | Histone deacetylase inhibitors for immunomodulation in tumor microenvironment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4142733T3 true PL4142733T3 (pl) | 2026-01-19 |
Family
ID=78373345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL21796395.8T PL4142733T3 (pl) | 2020-04-30 | 2021-04-28 | Inhibitory deacetylazy histonowej do immunomodulacji w mikrośrodowisku guza |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11672788B2 (enExample) |
| EP (1) | EP4142733B1 (enExample) |
| JP (1) | JP7748392B2 (enExample) |
| KR (1) | KR20230005939A (enExample) |
| CN (1) | CN116033904A (enExample) |
| AU (1) | AU2021265994B2 (enExample) |
| BR (1) | BR112022022015A2 (enExample) |
| ES (1) | ES3051512T3 (enExample) |
| HR (1) | HRP20251279T1 (enExample) |
| IL (1) | IL297687A (enExample) |
| MX (1) | MX2022013634A (enExample) |
| PL (1) | PL4142733T3 (enExample) |
| TW (1) | TWI849310B (enExample) |
| WO (1) | WO2021219040A1 (enExample) |
| ZA (1) | ZA202212650B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115322171B (zh) * | 2022-08-30 | 2023-03-17 | 深圳微芯生物科技股份有限公司 | 一种trka(g667c)和flt3靶点抑制剂及其与西达本胺的组合物 |
| CN122036601A (zh) * | 2024-11-15 | 2026-05-15 | 深圳微芯生物科技股份有限公司 | 一种苯甲酰胺类衍生物及其用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6174905B1 (en) | 1996-09-30 | 2001-01-16 | Mitsui Chemicals, Inc. | Cell differentiation inducer |
| EP1641458A2 (en) | 2002-12-27 | 2006-04-05 | Schering Aktiengesellschaft | Pharmaceutical combinations of phthalazine vegf inhibitors and benzamide hdac inhibitors |
| CA2552279C (en) * | 2003-12-02 | 2014-07-15 | The Ohio State University Research Foundation | Zn2+-chelating motif-tethered short -chain fatty acids as a novel class of histone deacetylase inhibitors |
| CA2702536A1 (en) | 2007-10-10 | 2009-04-16 | Orchid Research Laboratories Limited | Novel histone deacetylase inhibitors |
| CN106916100B (zh) * | 2014-04-04 | 2020-09-15 | 深圳微芯生物科技股份有限公司 | 一种e构型苯甲酰胺类化合物及其药用制剂 |
| CN106916101B (zh) | 2017-02-15 | 2020-05-01 | 聚缘（上海）生物科技有限公司 | Nampt/hdac双靶点抑制剂及其制备方法 |
| TR201900059A2 (tr) * | 2018-01-05 | 2019-07-22 | Gnt Biotech & Medicals Corp | Bi̇r farmasöti̇k kombi̇nasyon ve tümör mi̇kroortaminin ve i̇mmünoterapi̇ni̇n regülasyonu i̇çi̇n yöntem |
-
2021
- 2021-04-28 HR HRP20251279TT patent/HRP20251279T1/hr unknown
- 2021-04-28 MX MX2022013634A patent/MX2022013634A/es unknown
- 2021-04-28 WO PCT/CN2021/090718 patent/WO2021219040A1/en not_active Ceased
- 2021-04-28 JP JP2022565835A patent/JP7748392B2/ja active Active
- 2021-04-28 BR BR112022022015A patent/BR112022022015A2/pt not_active Application Discontinuation
- 2021-04-28 PL PL21796395.8T patent/PL4142733T3/pl unknown
- 2021-04-28 AU AU2021265994A patent/AU2021265994B2/en active Active
- 2021-04-28 ES ES21796395T patent/ES3051512T3/es active Active
- 2021-04-28 KR KR1020227042007A patent/KR20230005939A/ko active Pending
- 2021-04-28 EP EP21796395.8A patent/EP4142733B1/en active Active
- 2021-04-28 IL IL297687A patent/IL297687A/en unknown
- 2021-04-28 TW TW110115446A patent/TWI849310B/zh active
- 2021-04-28 US US17/243,378 patent/US11672788B2/en active Active
- 2021-04-28 CN CN202180031935.4A patent/CN116033904A/zh active Pending
-
2022
- 2022-11-21 ZA ZA2022/12650A patent/ZA202212650B/en unknown
-
2023
- 2023-05-01 US US18/310,387 patent/US12213971B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES3051512T3 (en) | 2025-12-29 |
| JP2023524230A (ja) | 2023-06-09 |
| JP7748392B2 (ja) | 2025-10-02 |
| CN116033904A (zh) | 2023-04-28 |
| US12213971B2 (en) | 2025-02-04 |
| EP4142733C0 (en) | 2025-10-01 |
| EP4142733A4 (en) | 2023-03-08 |
| IL297687A (en) | 2022-12-01 |
| KR20230005939A (ko) | 2023-01-10 |
| HRP20251279T1 (hr) | 2025-12-05 |
| CA3176748A1 (en) | 2021-11-04 |
| US11672788B2 (en) | 2023-06-13 |
| WO2021219040A1 (en) | 2021-11-04 |
| TW202200557A (zh) | 2022-01-01 |
| US20230263790A1 (en) | 2023-08-24 |
| ZA202212650B (en) | 2024-04-24 |
| US20210379032A1 (en) | 2021-12-09 |
| AU2021265994B2 (en) | 2024-02-29 |
| MX2022013634A (es) | 2022-11-16 |
| TWI849310B (zh) | 2024-07-21 |
| NZ794355A (en) | 2026-02-27 |
| EP4142733A1 (en) | 2023-03-08 |
| BR112022022015A2 (pt) | 2022-12-13 |
| AU2021265994A1 (en) | 2022-12-15 |
| EP4142733B1 (en) | 2025-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2099443A4 (en) | ASSOCIATION OF ERA + LIGANDS AND HISTONE DEACETYLASE INHIBITORS IN THE TREATMENT OF CANCER | |
| GB201901338D0 (en) | Histone deacetylase inhibitors for use in immunotherapy | |
| IL288425A (en) | Methods of treating virally associated cancers with histone deacetylase inhibitors | |
| EP2217588A4 (en) | INHIBITORS OF HISTONE DEACETYLASE | |
| ZA200906609B (en) | Inhibitors of histone deacetylase | |
| GB201803361D0 (en) | Histone deacetylase inhibitors | |
| EP2134680A4 (en) | Histone deacetylase INHIBITORS | |
| ZA201807855B (en) | Combinations comprising histone deacetylase inhibitors | |
| IL256439A (en) | Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of cancer | |
| MX2016007251A (es) | Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores. | |
| MX336994B (es) | Compuestos de indolil o indolinil hidroxamato. | |
| EP2451790A4 (en) | INHIBITORS OF HISTONE DEACETYLASE | |
| EP3148539A4 (en) | Histone deacetylase inhibitors and compositions and methods of use thereof | |
| EP3883572A4 (en) | PHARMACEUTICAL COMPOSITION WITH HISTONE DEACETYLASE-6 INHIBITORS | |
| IL267465A (en) | Histone deacetylase inhibitors | |
| PT3570834T (pt) | Inibidores bicíclicos de histona desacetilase | |
| EP3487492A4 (en) | USE OF ERIBULIN AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER | |
| EP3544612A4 (en) | PHARMACEUTICAL COMBINATIONS COMPRISING A HISTONE DEACETYLASE INHIBITOR AND A CD38 INHIBITOR AND METHODS OF USING THE SAME | |
| IL279940A (en) | Histone deacetylase inhibitors | |
| PL3535275T3 (pl) | Kombinacje farmaceutyczne zawierające inhibitor deacetylazy histonowej i inhibitor BCL-2 oraz sposoby ich stosowania | |
| SG11202012918PA (en) | Bicyclic inhibitors of histone deacetylase | |
| IL313081A (en) | New HDAC inhibitors and their medical use | |
| PT3664802T (pt) | Inibidores bicíclicos de histona-desacetilase | |
| IL277582A (en) | Combinations of pharmaceutical products containing a histone deacetylase suppressor and a TLR7 agonist and/or a TLR8 agonist for the treatment of cancer | |
| GB202009784D0 (en) | Histone deacetylase inhibitors |